Spots Global Cancer Trial Database for Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer
Official Title: A Phase III Randomized Study Comparing A Chemotherapy With Cisplatin And Etoposide To A Etoposide Regimen Without Cisplatin For Patients With Extensive Small-Cell Lung Cancer
Study ID: NCT00658580
Study Description
Brief Summary: The purpose of this study is to determine if a cisplatin-etoposide regimen improves survival in comparison to a regimen containing etoposide and without platinum derivative.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet, Brussels, , Belgium
Department of Pneumology CHRU Lille, Lille, , France
Hellenic Cancer Institute - St Savas Oncology Hospital, Athens, , Greece
Medical Oncology Hospital de Sagunto, Valencia, , Spain
Contact Details
Name: Jean-Paul Sculier, MD, PhD
Affiliation: European Lung Cancer Working Party
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
